Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.” ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

Amgen has developed biosimilars of J&J’s Stelara (Wezlana/ABP 654), Alexion’s Soliris (Bekemv/ABP 959) and Regeneron’s Eylea (ABP 938). Wezlana was approved in 2023 and launched in January 2025.